¹⁸F-NaF PET-CT versus ^99mTc SPECT in bone metastasis assessment - Authors' reply

Affiliations

¹ BC Cancer Research Institute, Vancouver, BC V5Z 1L3, Canada; Department of Radiology, University of British Columbia, Vancouver, BC, Canada. Electronic address: fbenard@bccrc.ca.
² BC Cancer Research Institute, Vancouver, BC V5Z 1L3, Canada.

Comment

François Bénard et al. Lancet Oncol. 2023 Feb.

. 2023 Feb;24(2):e69.

doi: 10.1016/S1470-2045(23)00017-7.

¹ BC Cancer Research Institute, Vancouver, BC V5Z 1L3, Canada; Department of Radiology, University of British Columbia, Vancouver, BC, Canada. Electronic address: fbenard@bccrc.ca.
² BC Cancer Research Institute, Vancouver, BC V5Z 1L3, Canada.

No abstract available

Comment on

Intra-individual comparison of ¹⁸F-sodium fluoride PET-CT and ^99mTc bone scintigraphy with SPECT in patients with prostate cancer or breast cancer at high risk for skeletal metastases (MITNEC-A1): a multicentre, phase 3 trial.
Bénard F, Harsini S, Wilson D, Zukotynski K, Abikhzer G, Turcotte E, Cossette M, Metser U, Romsa J, Martin M, Mar C, Saad F, Soucy JP, Eigl BJ, Black P, Krauze A, Burrell S, Nichol A, Tardif JC. Bénard F, et al. Lancet Oncol. 2022 Dec;23(12):1499-1507. doi: 10.1016/S1470-2045(22)00642-8. Epub 2022 Nov 4. Lancet Oncol. 2022. PMID: 36343655 Clinical Trial.
¹⁸F-NaF PET-CT versus ^99mTc SPECT in bone metastasis assessment.
Wang J, Hesketh RL. Wang J, et al. Lancet Oncol. 2023 Feb;24(2):e68. doi: 10.1016/S1470-2045(23)00003-7. Lancet Oncol. 2023. PMID: 36725148 No abstract available.